RT Journal Article
SR Electronic
T1 Efficacy and safety of endocrine therapy after mastectomy in patients with hormone receptor positive breast ductal carcinoma in situ:retrospective cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.10.06.22280792
DO 10.1101/2022.10.06.22280792
A1 Niu, Nan
A1 Zhang, Yinan
A1 Bai, Yang
A1 Wang, Xin
A1 Yan, Shunchao
A1 Song, Dong
A1 Xu, Hong
A1 Liu, Tong
A1 Hua, Bin
A1 Zhang, Yingchao
A1 Liu, Jinchi
A1 Qiao, Xinbo
A1 Liu, Jiaxiang
A1 Zheng, Xinyu
A1 Cao, Hongyi
A1 Liu, Caigang
YR 2022
UL http://medrxiv.org/content/early/2022/10/07/2022.10.06.22280792.abstract
AB Background More than half of Chinese patients with hormone receptor positive (HR+) ductal carcinoma in situ (DCIS) are treated with mastectomy, and usually followed by endocrine therapy (ET). Given that long-term ET can cause severe adverse effects it is important to determine the beneficial effect and safety of adjuvant ET after mastectomy on the disease-free survival (DFS) and adverse events in patients with HR+ DCIS.Methods To explore beneficial effect and safety of ET after mastectomy in patients with HR+ DCIS, we performed a multicenter, population-based study. This retrospective study analyzed the DFS and adverse events in 1037 HR+ DCIS Chinese patients with or without post-mastectomy ET from eight Breast Centers between 2006-2016. The median follow-up time was 86 months.Results There were 791 DCIS patients receiving ET (ET group). Those patients were followed-up for a median of 86 months (range, 60-177 months). There were 23 cases with tumor recurrence or distant metastasis. There were similar 5-year DFS rates and DFS between the ET and non-ET groups, even for those with high risk factors. Conversely, 37.04% of patients suffered from adverse events after ET, which were significantly higher than those in the non-ET group.Conclusion ET after mastectomy did not benefit patients with HR+ DCIS for their DFS, rather increased adverse events in those patients. Therefore, ET after mastectomy may not be recommended for patients with HR+ DCIS, even for those with high-risk factors, such as multifocal, microinvasive and higher T stage.Funding This study was supported by grants from Outstanding Scientific Fund of Shengjing Hospital (201803) and Outstanding Young Scholars of Liaoning Province (2019-YQ-10).Competing Interest StatementThe authors have declared no competing interest.Funding StatementOutstanding Young Scholars of Liaoning Province: Caigang Liu 2019-YQ-10 Outstanding Scientific Fund of Shengjing Hospital: Caigang Liu 201803 The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board of Shengjing Hospital (approval number: 2020PS014K).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analysed during this study are included in the manuscript and supporting files.